296 filings
DEFA14A
PCSA
Processa Pharmaceuticals Inc
29 Apr 24
Additional proxy soliciting materials
4:31pm
DEF 14A
PCSA
Processa Pharmaceuticals Inc
Definitive proxy
29 Apr 24
4:30pm
8-K
PCSA
Processa Pharmaceuticals Inc
11 Apr 24
Regulation FD Disclosure
8:00am
8-K
PCSA
Processa Pharmaceuticals Inc
4 Apr 24
Regulation FD Disclosure
12:05pm
10-K
2023 FY
PCSA
Processa Pharmaceuticals Inc
Annual report
29 Mar 24
4:06pm
8-K
f8istkqm
21 Feb 24
Regulation FD Disclosure
5:25pm
8-K
oykqv1e9bbwn4kmbb f0
6 Feb 24
Other Events
8:30am
8-K
c67lzy8crh1q9zit
30 Jan 24
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
10:46am
424B4
fx0mnuc6dwyy8v2 fxcp
29 Jan 24
Prospectus supplement with pricing info
4:15pm
EFFECT
ruff3s
29 Jan 24
Notice of effectiveness
12:15am
8-K
ga42tvhe db
25 Jan 24
NGC-Cap was better tolerated with positive preliminary efficacy results than FDA-approved capecitabine
8:35am
CORRESP
wiz4emf jhort
22 Jan 24
Correspondence with SEC
12:00am
CORRESP
edgwi1sh
22 Jan 24
Correspondence with SEC
12:00am
8-K
4544w8m2it2g1n35
19 Jan 24
Processa Pharmaceuticals Announces Expansion of NGC-Cap Program into Advanced or Metastatic Breast Cancer
8:00am
8-K
zkicwubnhu3df8d ab3
18 Jan 24
Material Modifications to Rights of Security Holders
8:30am
8-K
nmw7 qomd88c9s63hkc
8 Jan 24
Regulation FD Disclosure
4:30pm
UPLOAD
u9hhiuzftg1e vua7b
5 Jan 24
Letter from SEC
12:00am
8-K
8s2wij9 4wkrclfwfpx
19 Dec 23
FDA acknowledges that NGC-Cap is a New Chemical Entity given the changes to metabolism and distribution of its major metabolite 5-FU
9:00am